Zhejiang Haisen Pharmaceutical Co. Ltd. A
Zhejiang Haisen Pharmaceutical Co., Ltd. engages in the research and development, production, sale, and import and export of pharmaceutical intermediates, active pharmaceutical ingredients, and preparations in China and internationally. The company offers active pharmaceutical ingredients for anti-gastric ulcer, antilipemic agent, antipyretic analgesics, antidepressant, analgesic, cardiovascular,… Read more
Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) - Total Assets
Latest total assets as of June 2025: CN¥1.52 Billion CNY
Based on the latest financial reports, Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) holds total assets worth CN¥1.52 Billion CNY as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zhejiang Haisen Pharmaceutical Co. Ltd. A - Total Assets Trend (2021–2024)
This chart illustrates how Zhejiang Haisen Pharmaceutical Co. Ltd. A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Zhejiang Haisen Pharmaceutical Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Haisen Pharmaceutical Co. Ltd. A's total assets of CN¥1.52 Billion consist of 84.6% current assets and 15.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 69.6% |
| Accounts Receivable | CN¥53.50 Million | 3.6% |
| Inventory | CN¥115.48 Million | 7.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥20.14 Million | 1.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Zhejiang Haisen Pharmaceutical Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Haisen Pharmaceutical Co. Ltd. A's current assets represent 84.6% of total assets in 2024, an increase from 75.6% in 2021.
- Cash Position: Cash and equivalents constituted 69.6% of total assets in 2024, up from 43.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 4.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 7.8% of total assets.
Zhejiang Haisen Pharmaceutical Co. Ltd. A Competitors by Total Assets
Key competitors of Zhejiang Haisen Pharmaceutical Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
Zhejiang Haisen Pharmaceutical Co. Ltd. A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Zhejiang Haisen Pharmaceutical Co. Ltd. A generates 0.32x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Zhejiang Haisen Pharmaceutical Co. Ltd. A generates $8.25 in net profit.
Zhejiang Haisen Pharmaceutical Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.95 | 14.45 | 14.45 |
| Quick Ratio | 9.86 | 12.63 | 12.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.08 Billion | CN¥ 1.11 Billion | CN¥ 1.11 Billion |
Zhejiang Haisen Pharmaceutical Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Zhejiang Haisen Pharmaceutical Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.44 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | 10.8% |
| Total Assets | CN¥1.49 Billion |
| Market Capitalization | $146.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Haisen Pharmaceutical Co. Ltd. A's assets below their book value (0.10 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Zhejiang Haisen Pharmaceutical Co. Ltd. A's assets grew by 10.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Zhejiang Haisen Pharmaceutical Co. Ltd. A (2021–2024)
The table below shows the annual total assets of Zhejiang Haisen Pharmaceutical Co. Ltd. A from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.49 Billion | +10.82% |
| 2023-12-31 | CN¥1.34 Billion | +137.08% |
| 2022-12-31 | CN¥565.60 Million | +18.50% |
| 2021-12-31 | CN¥477.31 Million | -- |